SMA type 2, also called Dubowitz disease, is a genetic condition that causes progressive muscle weakness due to the loss of motor neurons in the spinal cord. Symptoms appear between 6 and 18 months of age. Children with SMA type 2 can learn to sit independently but are unable to walk. It falls in the middle of the SMA severity spectrum, more severe than type 3 but less severe than type 1.
What Causes SMA Type 2
SMA is caused by mutations in a gene called SMN1, which provides instructions for making a protein that motor neurons need to survive. Without enough of this protein, the nerve cells that control voluntary muscle movement gradually break down and die. Everyone carries a backup gene called SMN2 that produces the same protein, but in a shortened, less stable form that can’t fully compensate for the missing SMN1 gene.
The number of SMN2 copies a person has plays a major role in determining severity. Most people with SMA type 2 carry three copies of SMN2. A meta-analysis found that about 60% of patients with three SMN2 copies develop type 2 disease, 35% develop the milder type 3, and 5% still develop a more severe form. The relationship isn’t perfectly predictable, though. Some patients with only two copies have milder disease than expected, while some with four or more copies still develop more severe forms. This variability means SMN2 copy number is a useful guide but not a guarantee of how the disease will progress.
How SMA Type 2 Affects the Body
The hallmark of SMA type 2 is low muscle tone (hypotonia) and worsening muscle weakness that tends to affect the legs more than the arms. Babies with this form typically hit early milestones like holding their head up and rolling over, but the weakness becomes apparent as they grow and fail to progress to standing or walking. Most children can sit without support once placed in a seated position, and many retain good hand and arm function for years.
The weakness isn’t limited to the limbs. The muscles between the ribs that help with breathing are also affected, while the diaphragm is relatively spared early on. This creates a characteristic breathing pattern where the belly moves outward with each breath but the chest doesn’t expand normally. Over time, the weakened chest wall muscles make it harder to cough effectively and clear mucus from the lungs, increasing the risk of respiratory infections.
Scoliosis, or curvature of the spine, develops in nearly all non-ambulatory children with SMA. Some estimates put the rate as high as 90%. The combination of weak trunk muscles and continued growth causes the spine to curve progressively, which can further compress the lungs and reduce breathing capacity. Many children with SMA type 2 eventually need spinal fusion surgery to stabilize the curve.
How SMA Type 2 Is Diagnosed
Diagnosis starts with recognizing the pattern: an infant who was developing normally begins to plateau or lose motor skills between 6 and 18 months. A doctor may notice low muscle tone, weak reflexes, or a fine tremor in the fingers during a physical exam.
Confirmation requires genetic testing. A simple blood test can identify about 95% of all SMA cases by checking for a deletion or mutation in both copies of the SMN1 gene. The remaining 5% of cases involve a rare point mutation on one SMN1 copy that standard testing misses. These require a more detailed gene sequencing analysis. The same blood test can also count SMN2 copies, which helps predict severity and guide treatment decisions.
Newborn screening programs now test for SMA at birth in many places, which means some children are identified before symptoms even appear. Pre-symptomatic treatment has shown significantly better outcomes than waiting until weakness is already evident.
Available Treatments
Until 2016, treatment for SMA was entirely supportive. That changed with the approval of the first disease-modifying therapy, a drug delivered by spinal injection that targets the SMN2 backup gene. It works by coaxing SMN2 to produce more of the full-length, functional protein that motor neurons need to survive. A Phase 3 clinical trial in children with SMA type 2 (called CHERISH) met its primary endpoint early, meaning the benefits were clear enough that the trial didn’t need to run its full course. In treated patients, 71% showed meaningful improvements in motor function scores, compared with just 3% in the control group.
Two additional therapies have since been approved. One is an oral liquid medication taken daily at home that works through a similar mechanism, boosting the amount of functional protein produced by the SMN2 gene. The other is a one-time gene therapy delivered by IV infusion that provides a working copy of the SMN1 gene directly. Gene therapy was originally studied in infants with type 1, but its use has expanded. In clinical studies, treated infants showed rapid improvements in motor function scores, gaining an average of 24.6 points in the higher-dose group over 20 months.
These treatments don’t cure SMA, but they can slow progression, preserve existing motor function, and in some cases help children gain new abilities they wouldn’t have achieved otherwise. The earlier treatment begins, the better the outcomes tend to be, because it’s easier to protect motor neurons that are still alive than to restore function after they’ve been lost.
Daily Life and Ongoing Care
Children with SMA type 2 typically use a wheelchair for mobility, often starting with a power chair around age 2 or 3. Many develop strong communication skills, do well academically, and are socially engaged. Arm and hand function is usually preserved well enough for writing, using a computer, and feeding themselves, though this can decline over time without treatment.
Respiratory care is a central part of management. Many children benefit from a cough-assist device that helps clear secretions from the lungs. Some need breathing support during sleep, typically through a mask that delivers air under gentle pressure. Respiratory infections need prompt attention because weak cough muscles make pneumonia a serious risk.
Nutritional monitoring matters too. Some children have difficulty chewing or swallowing as the muscles of the jaw and throat weaken. Others face the opposite problem: reduced activity levels combined with normal appetite can lead to excess weight gain, which puts additional strain on weakened muscles. A dietitian familiar with SMA can help find the right balance.
Long-Term Outlook
Before disease-modifying therapies existed, SMA type 2 was a condition of gradual decline. Most individuals survived into adulthood, but respiratory complications were the leading cause of reduced life expectancy. Many people with type 2 live into their 20s, 30s, and beyond, particularly with proactive respiratory and orthopedic care.
The treatment landscape has shifted the trajectory meaningfully. Children diagnosed and treated early are reaching motor milestones that were previously out of reach for this type. It’s still too soon to know the full long-term impact of these therapies on life expectancy and quality of life, since the oldest treated patients are only now entering their teenage years. What’s clear from clinical data so far is that motor function stabilizes or improves in most treated children rather than following the steady decline that was once considered inevitable.